Evidence map›Paper›PMID 39290318›Full record

ArticleMolecular therapy. Oncology2024

Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer.

Ghassan M Saed, Nicole M Fletcher, Harvey Sharma, Axel Stenmark Tullberg, Ella Ittner, Toshima Z Parris, Daniella Pettersson, Anikó Kovács, Elisabeth Werner Rönnerman, Pernilla Dahm-Kähler and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ghassan M SaedDepartment of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.
Nicole M FletcherDepartment of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.
Harvey SharmaDepartment of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.
Axel Stenmark TullbergDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Ella IttnerDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Toshima Z ParrisDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Daniella PetterssonSahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Anikó KovácsDepartment of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Elisabeth Werner RönnermanDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Pernilla Dahm-KählerDepartment of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Anna PortelaXenopat C/Feixa Llarga sn. Edifici Bioincubadora, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
Pamela D GarzoneAnixa Biosciences, Inc., San Jose, CA, USA.
Robert MorrisDepartment of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA.
Khalil HelouDepartment of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lemur tail kinase 3 (LMTK3) belongs to a family of tyrosine kinases that are known to correlate with tumor grade and patient survival in some cancers. Here, we validated LMTK3 as a specific target and a prognostic biomarker in ovarian cancer (OC). In samples from 204 stage I-II OC patients, immunohistochemical studies revealed a higher cytoplasmic-to-nuclear staining intensity of LMTK3, which correlated with worse overall survival (

Indexed as

binding peptideschemoresistancelemur tail kinase 3ovarian cancertargeted therapy

Identifiers

PMID39290318
PMCPMC11406030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.